Giuseppe Curigliano, MD, PhD, is the director of the Early Drug Development Division and holds the co-chair for Experimental Therapeutics Program at the European Institute of Oncology, a comprehensive cancer center in Milano, Italy. He is steering committee member of the Department of Oncology and Hemato-Oncology at the University of Milano. Moreover, he is member of the Italian National Health Council, serving as advisor of the Ministry of Health for cancer policy issues.

He worked at the Columbia University Comprehensive Cancer Center in New York, USA, developing an experience in preclinical and translational research. He was also visiting scholar at the Dana Farber Cancer Institute, Harvard Medical School in Boston, USA. At the European Institute of Oncology he served as Co-Director of the Division of Medical Oncology until 2014.

Professor Curigliano obtained his medical and specialist degree from the Catholic University in Rome, Italy. He is a specialist in Medical Oncology. He obtained a PhD in Clinical Pharmacology at University of Pisa, Italy.

Professor Curigliano served as an expert panel member issuing the AIOM, ESMO, ASCO guidelines in breast cancer and germline gene testing recommendations. He co-chaired for several years the scientific committee of the St Gallen Early Breast Cancer Conference. He is also a scientific board member of EUSOMA (European Society of Breast Cancer Specialists). He is serving as member of the Scientific Board of the International Breast Cancer Study Group (IBCSG). He is serving on the executive board of the Breast International Group (BIG).

In ESMO he served as Chair of the ESMO Nomination Committee (2018-2021) and as Chair of the ESMO Clinical Practice Guidelines Committee (2020-2023). He was one of the founding members and served as scientific Co-Chair of the “ESMO Breast Cancer Congress”. He contributed to launch the ESMO Living Guidelines and to the recognition of the Fellow of ESMO (FESMO). He organized and participated to many professional and educational programs for oncologists all over the world.

Professor Curigliano is principal investigator and steering committee member of numerous breast and early development clinical trials, particularly with innovative targeted compounds and individualized treatment strategies. His translational research focusses on the field of biomarkers and personalised therapies, biomarker discovery, development of targeted agents and implementation of personalised medicine. His team includes 40 people (including medical staff, research nurse, oncology nurse and medical oncology residents) working on basic sciences, bioinformatics, biotechnologies and clinical research. He is also leading phase I-III trials testing targeted agents in the field of breast cancer, agnostic and large national trials testing implementation of high throughput technologies in the health care system.

He has a strong interest in artificial intelligence and established in the University of Milano the first Master on Artificial Intelligence in Cancer Medicine.

Professor Curigliano was identified as Clarivate™ world’s most influential researchers (the highly cited researchers) in 2022 and 2023. He has authored more than 670 papers in peer-reviewed journals (h-index 83) and many book chapters. He served as editorial board member for international journals in oncology (European Journal of Oncology, Journal of Clinical Oncology, Annals of Oncology). He is a panel member of several international breast cancer consensus conferences and has served as a chair or steering committee member for numerous national and international conferences. He has trained, mentored and sponsored dozens of medical oncologists from Latin America, Africa, Asia and Italy.

Professor Curigliano was awarded with the first ESO Umberto Veronesi Award (2017) and with the Fellowship of the European Academy of Cancer Sciences in Paris (2017).

Prof. Curigliano is currently serving as Editor in Chief of ESMO Open.

Prof. Curigliano was born in Rouyn Noranda, Canada; he is married with an intensive care doctor. He has dual citizenship (Italy and Canada).